These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 27788239)

  • 21. Effect of efavirenz, nevirapine, etravirine, and raltegravir administration on the pharmacokinetics of ritonavir-boosted darunavir in a population of HIV-infected patients.
    Dailly E; Allavena C; Bouquié R; Deslandes G; Raffi F; Jolliet P
    AIDS Res Hum Retroviruses; 2013 Jan; 29(1):42-6. PubMed ID: 23148588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A 48-week pilot study switching suppressed patients to darunavir/ritonavir and etravirine from enfuvirtide, protease inhibitor(s), and non-nucleoside reverse transcriptase inhibitor(s).
    Ruane P; Alas B; Ryan R; Perniciaro A; Witek J
    AIDS Res Hum Retroviruses; 2010 Nov; 26(11):1215-9. PubMed ID: 21083412
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes.
    Poveda E; de Mendoza C; Parkin N; Choe S; García-Gasco P; Corral A; Soriano V
    AIDS; 2008 Mar; 22(5):611-6. PubMed ID: 18317002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional study.
    Antinori A; Meraviglia P; Monforte Ad; Castagna A; Mussini C; Bini T; Gianotti N; Rusconi S; Colella E; Airoldi G; Mancusi D; Termini R
    Drug Des Devel Ther; 2016; 10():1589-603. PubMed ID: 27226708
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Darunavir/cobicistat monotherapy. Experience in a tertiary hospital].
    Yunquera-Romero L; Asensi-Díez R; Del Rio-Valencia JC; Muñoz-Castillo I; Castaño-Carracedo MA
    Rev Esp Quimioter; 2016 Dec; 29(6):308-317. PubMed ID: 27888600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Switch from etravirine twice daily to once daily in non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-infected patients with suppressed viremia: the Monetra study.
    Schneider L; Ktorza N; Fourati S; Assoumou L; Courbon E; Caby F; Blanc C; Tindel M; Agher R; Marcelin AG; Calvez V; Peytavin G; Katlama C
    HIV Clin Trials; 2012; 13(5):284-8. PubMed ID: 23134629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level.
    Nair SS; Sarasamma S; Gracious N; George J; Anish TS; Radhakrishnan R
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():197-200. PubMed ID: 25894154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of CYP3A5*3 genotype on serum carbamazepine concentrations at steady-state in Korean epileptic patients.
    Park PW; Seo YH; Ahn JY; Kim KA; Park JY
    J Clin Pharm Ther; 2009 Oct; 34(5):569-74. PubMed ID: 19744012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug susceptibility to etravirine and darunavir among Human Immunodeficiency Virus Type 1-derived pseudoviruses in treatment-experienced patients with HIV/AIDS in South Korea.
    Kwon OK; Kim SS; Rhee JE; Kee MK; Park M; Oh HR; Choi JY
    Virol J; 2015 Apr; 12():53. PubMed ID: 25879840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Boosted protease inhibitor monotherapy in HIV-infected patients: results of a study in a real life setting].
    Di Benedetto N; Montero-Alonso M; Blanes M; Lacruz J; Cuellar S; Calabuig E; López J; Salavert M
    Rev Esp Quimioter; 2015 Oct; 28(5):235-41. PubMed ID: 26437753
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
    Bunupuradah T; Ananworanich J; Chetchotisakd P; Kantipong P; Jirajariyavej S; Sirivichayakul S; Munsakul W; Prasithsirikul W; Sungkanuparph S; Bowonwattanuwong C; Klinbuayaem V; Petoumenos K; Hirschel B; Bhakeecheep S; Ruxrungtham K
    Antivir Ther; 2011; 16(7):1113-21. PubMed ID: 22024527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Safety and tolerability of etravirine].
    Portilla J
    Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():21-6. PubMed ID: 20116624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Different effects of glucocorticoids on darunavir plasma concentrations.
    Cattaneo D; Cheli S; Fusi M; Clementi E; Gervasoni C
    Eur J Clin Pharmacol; 2019 May; 75(5):733-735. PubMed ID: 30627757
    [No Abstract]   [Full Text] [Related]  

  • 34. Persistence, adherence, and all-cause healthcare costs in atazanavir- and darunavir-treated patients with human immunodeficiency virus in a real-world setting.
    Farr AM; Johnston SS; Ritchings C; Brouillette M; Rosenblatt L
    J Med Econ; 2016; 19(4):386-96. PubMed ID: 26640980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
    Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
    Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.
    De Meyer S; Lathouwers E; Dierynck I; De Paepe E; Van Baelen B; Vangeneugden T; Spinosa-Guzman S; Lefebvre E; Picchio G; de Béthune MP
    AIDS; 2009 Sep; 23(14):1829-40. PubMed ID: 19474650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Etravirine in highly treatment-experienced patients].
    Palter DP; Corbera EF; Tiraboschi JM
    Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():6-11. PubMed ID: 20116622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simplification from twice-daily to once-daily darunavir/ritonavir in a randomized trial among HIV-infected persons with HIV-1 RNA suppression on antiretroviral therapy.
    Huhn GD; Sigman A; Livak B
    Antivir Ther; 2015; 20(8):849-54. PubMed ID: 25881614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients.
    Solas C; Simon N; Drogoul MP; Quaranta S; Frixon-Marin V; Bourgarel-Rey V; Brunet C; Gastaut JA; Durand A; Lacarelle B; Poizot-Martin I
    Br J Clin Pharmacol; 2007 Sep; 64(3):353-62. PubMed ID: 17517050
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short communication: Phenotypic protease inhibitor resistance and cross-resistance in the clinic from 2006 to 2008 and mutational prevalences in HIV from patients with discordant tipranavir and darunavir susceptibility phenotypes.
    Bethell R; Scherer J; Witvrouw M; Paquet A; Coakley E; Hall D
    AIDS Res Hum Retroviruses; 2012 Sep; 28(9):1019-24. PubMed ID: 22098079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.